摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,2,3,4,7,8,9,10-octahydro-6-methyl-phenanthridine | 16864-84-9

中文名称
——
中文别名
——
英文名称
1,2,3,4,7,8,9,10-octahydro-6-methyl-phenanthridine
英文别名
6-methyl-1,2,3,4,7,8,9,10-octahydrophenanthridine;6-methyl-1,2,3,4,7,8,9,10-octahydro-phenanthridine;6-Methyl-1,2,3,4,7,8,9,10-octahydro-phenanthridin;6-methyloctahydrophenanthridine;1,2,3,4,7,8,9,10-Octahydro-6-methylphenanthridin
1,2,3,4,7,8,9,10-octahydro-6-methyl-phenanthridine化学式
CAS
16864-84-9
化学式
C14H19N
mdl
——
分子量
201.312
InChiKey
KAXLEJWWSAJDMP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    68 °C
  • 沸点:
    197 °C(Press: 20 Torr)
  • 密度:
    1.045±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.9
  • 重原子数:
    15
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.64
  • 拓扑面积:
    12.9
  • 氢给体数:
    0
  • 氢受体数:
    1

SDS

SDS:61e484c51a29f737faacfca60015b967
查看

反应信息

  • 作为反应物:
    描述:
    1,2,3,4,7,8,9,10-octahydro-6-methyl-phenanthridine正丁基锂 作用下, 生成 1,2,3,4,7,8,9,10-octahydro-6-methylphenanthridine-4-thiocarboxamide
    参考文献:
    名称:
    Phenanthridine derivatives and related compounds
    摘要:
    该发明提供了一种式I的化合物,其中R.sup.1和R.sup.2相同或不同,代表1-6个碳原子的氢或烷基,R.sup.3代表氢、1-6个碳原子的烷基或苯基,X为Na、K、Li或CSNHR.sup.4,其中R.sup.4为氢或1-6个碳原子的烷基,n为3、4或5,或者X为CSNHR.sup.4时的化合物的药学接受酸盐。其中X为CSNHR.sup.4时的式I化合物为抗溃疡剂。其中X为Na、K或Li时为中间体。
    公开号:
    US04046895A1
  • 作为产物:
    描述:
    acetamido-1 (cyclohexene-1 yl)-2 cyclohexene三氯氧磷 作用下, 以 甲苯 为溶剂, 反应 1.0h, 以87%的产率得到1,2,3,4,7,8,9,10-octahydro-6-methyl-phenanthridine
    参考文献:
    名称:
    dienamides as versatile precursors of polycyclic pyridines and isoquinolines
    摘要:
    DOI:
    10.1016/s0040-4039(01)93373-8
点击查看最新优质反应信息

文献信息

  • Selective synthesis of octahydroacridines and diannelated pyridines over zinc-containing mesoporous aluminosilicate molecular sieve catalysts
    作者:Manickam Selvaraj、Mohammed A. Assiri
    DOI:10.1039/c9dt01196j
    日期:——
    the highly selective synthesis of 1,2,3,4,5,6,7,8-octahydroacridine (OHA) by the vapour phase aminocyclization of cyclohexanone (CyO) with a mixture of formaldehyde (HCHO) and ammonia (NH3) over mesoporous bimetallic ZnAlMCM-41 (ZnAl-41) molecular sieves as efficient catalysts, which were synthesised by a simple basic hydrothermal method. To find optimum parameters for the synthesis of OHA, different
    我们展示了一种非常环保的单步催化方法,可通过环己酮(Cy O)的气相氨基环化来高度选择性地合成1,2,3,4,5,6,7,8-八氢ac啶(OHA )以简单的碱性水热法合成了介孔双金属ZnAlMCM-41(ZnAl-41)分子筛上的甲醛(HCHO)和氨(NH 3)混合物作为有效催化剂。为了找到合成OHA的最佳参数,需要使用不同的反应参数,例如温度,生产时间(TOS),重时空速(WHSV)以及Cy O:HCHO:NH 3的进料摩尔比。,已被广泛研究。用过的ZnAl-41催化剂经过洗涤和煅烧处理,以回收可循环利用的催化剂,然后将其重新用于这些反应中以研究其催化能力。为了选择性地合成多种吡啶化合物,具有不同反应参数的活性介孔催化剂ZnAl-41(75)和可循环利用的ZnAl-41(75)被广泛用于具有不同醛和环酮的气相氨基环化反应中。 ,并产生出色的产品选择性,例如,9-烷基取代的八氢s啶(9-A
  • Vapor Phase Synthesis of Annelated Pyridines over Metal Modified Zeolite Beta
    作者:Arun Kumar Macharla、Mahender Reddy Marri、Swamy Peraka、Naresh Mameda、Srujana Kodumuri、V. V. Krishna Mohan Kandepi、Narender Nama
    DOI:10.1007/s10562-015-1598-0
    日期:2015.10
    synthesis of annelated pyridines from cyclic ketones, aldehydes and ammonia was carried out over various zeolite molecular sieves like Hβ, HZSM-5 (240), HZSM-5 (40), HY, HX, HMCM-41 and Mordenite. The preliminary screening of catalyst clearly shows that Hβ catalyst was found to be more active for the vapor phase synthesis of annelated pyridines. Hβ was further modified with transition metals like Fe, Cu
    在各种沸石分子筛如 Hβ、HZSM-5 (240)、HZSM-5 (40)、HY、HX、HMCM-41 和丝光沸石上,从环酮、醛和氨气中进行退火吡啶的气相合成。催化剂的初步筛选清楚地表明,发现 Hβ 催化剂对退火吡啶的气相合成更具活性。Hβ 用 Fe、Cu、Pb、Mo、Zn、Ni、Co、Ce、W 和 Sn 等过渡金属进一步改性以获得更高的产率。
  • Liquid phase process for the synthesis of annulated pyridines over molecular sieve catalysts
    申请人:Kulkarni J. Shivanand
    公开号:US20060149068A1
    公开(公告)日:2006-07-06
    The present invention relates to a process for producing annulated pyridines by reacting cyclic ketone, aldehyde and ammonia in presence of molecular sieve type catalysts in an environmentally friendly, economical and highly selective heterogeneous method.
    本发明涉及一种在环保、经济和高选择性的异相方法中,在分子筛型催化剂存在下,通过反应环状酮、醛和氨生成环化吡啶的方法。
  • Regio- and stereoselective annelation of phenanthridines with α,β-acetylenic γ-hydroxyacid nitriles
    作者:Ludmila V. Andriyankova、Anastasiya G. Mal'kina、Lina P. Nikitina、Kseniya V. Belyaeva、Igor A. Ushakov、Andrei V. Afonin、Mikhail V. Nikitin、Boris A. Trofimov
    DOI:10.1016/j.tet.2005.06.012
    日期:2005.8
    Phenanthridines (3,4-, 7,8-benzoquinolines and methyloctahydrophenanthridine) are annelated regio- and stereoselectively with α,β-acetylenic γ-hydroxyacid nitriles to form new polyfunctional condensed systems, 4-cyanomethylene-1,3-oxazolidino-1,2-dihydrophenanthridines.
    菲啶(3,4-,7,8-苯并喹啉和甲基八氢菲啶)与α,β-炔属γ-羟酸腈区域和立体选择性地退火,形成新的多官能团缩合体系,4-氰基亚甲基-1,3-恶唑烷醇-1, 2-二氢菲啶。
  • Pyrimidine derivatives
    申请人:Sato Michitaka
    公开号:US20070197551A1
    公开(公告)日:2007-08-23
    This invention provides pyrimidine derivatives represented by a formula, in the formula, ring A stands for carbocyclic group or heterocyclic group, X 1 stands for hydrogen, lower alkyl, amino, etc., X 2 stands for hydrogen or lower alkyl, Y stands for a direct bond or sulfur or nitrogen, n stands for an integer of 0-4, and Ar stands for a group of the following formula, or a salt thereof, which concurrently exhibit 5-HT 1A agonistic activity and 5-HT 3 antagonistic activity and are useful for therapy and treatments of diseases such as IBS. The invention furthermore provides a therapeutic method of IBS, characterized by having 5-HT 1A agonistic activity and 5-HT 3 antagonistic activity work simultaneously and cooperatively in vivo, which comprises either administering 5-HT 3 antagonistic agent which concurrently exhibits 5-HT 1A agonistic activity, or administering 5-HT 1A agonistic agent and 5-HT 3 antagonistic agent simultaneously, in sequence or at an interval.
    本发明提供了由下式表示的嘧啶衍生物,其中,环A代表碳环基团或杂环基团,X1代表氢、低碳基、氨基等,X2代表氢或低碳基,Y代表直接键或硫或氮,n代表0-4的整数,Ar代表以下式的基团,或其盐,同时表现出5-HT1A激动活性和5-HT3拮抗活性,并且对治疗诸如肠易激综合征等疾病有用。本发明进一步提供了一种IBS治疗方法,其特征在于在体内同时和协同地发挥5-HT1A激动活性和5-HT3拮抗活性,包括给予同时表现出5-HT1A激动活性和5-HT3拮抗活性的5-HT3拮抗剂,或同时给予5-HT1A激动剂和5-HT3拮抗剂,按顺序或间隔给予。
查看更多